Skip to main content

Table 5 Studies analyzing cancer risk in patients with primary SjS based on the fulfillment of the 2002 criteria

From: Characterization and risk estimate of cancer in patients with primary Sjögren syndrome

Author

Year

Country

Setting

Primary SjS patients (n)

Mean folow-up (yrs/pat-years)

Population cancer registry/classif

Hemat neoplasia classif

Cancer (n)

All-cancer SIR (95% CI)

Specific solid cancer SIR

Hemat cancers (n)

NHL (n)

MALT (n)

DLBC (n)

MZ (n)

Myel (n)

Other B-cell

Non-B-cell

NHL SIR (95% CI)

MM SIR (95% CI)

Theander

2006

Sweden

Hosp

286

jul-64

Swedish Cancer Reg/ICD7

WHO 2001

33

1.42 (0.98–2.00)

NA

12

11

1

7

0

2

1

T-cell (1)

15.6 (7.8–27.8)

3.27 (0.1–18.2)

Baimpa

2009

Greece

Hosp

536

2.6/ND

NA

ND

ND

NA

NA

40

38

21

7

5

0

5

HD (1), T-cell (1)

NA

ND

Zhang

2010

China

Hosp

1320

4.4/ND

Shangai Reg/ICD10

WHO 2001

29

3.25 (2.12–4.52)

NA

10

8

2

2

0

0

3

T-cell (1)

48.1 (20.7–94.8)

37.9 (4.58–136.7)

Weng

2012

Taiwan

Pop

7852

ND/27246

NHI/ICD9

ICD9

227

1.01 (0.74–1.35)

Colon 0.22 (0.05–0.6); Thyroid 2.56 (1.4–4.3)

31

23

ND

ND

ND

ND

ND

ND

7.1 (4.2–10.3)

6.1 (2.0–14.2)

Baldini

2012

Italy

Hosp

563

6/ND

NA

WHO 2001

NA

NA

NA

NA

12

8

3

1

0

0

ND

NA

ND

Hemminki

2012

Sweden

Pop

1516

ND/16700

Swedish Cancer Reg/ICD

NA

NA

NA

Breast 0.46 (0.26–0.75)

NA

NA

ND

ND

ND

ND

ND

ND

NA

ND

Johnsen

2013

Norway

Pop

443

ND/3813

Norway Reg/ICD10

ICD10

NA

NA

NA

NA

7

6

0

1

0

0

ND

9.0 (7.1–26.3)

ND

Risselada

2013

Netherl

Hosp

195

7.7/ND

NA

WHO 2001

NA

NA

NA

NA

21

10

8

3

0

0

ND

NA

ND

Quartuccio

2014

Italy

Hosp

661

ND

NA

ND

NA

NA

NA

NA

40

ND

ND

ND

ND

ND

ND

NA

ND

Papageorgiou

2015

Greece

Hosp

ND

ND

ND

WHO

ND

ND

ND

ND

77

51

12

8

0

6

 

ND

 

Nocturne

2016

France

Hosp

ND

ND

ND

WHO

ND

ND

ND

ND

99

58

17

18

0

6

HD (1), T-cell (1)

ND

ND

Present study

2016

Spain

Hosp

1300

7.6/ND

GLOBOCAN/ICD10

WHO 2016

122

1.91 (1.6–2.28)

Thyroid 5.17 (1.94–13.79); Lip/oral 4.81 (1.81–12.83); Stomach 2.53 (1.05–6.07)

61

12

27

7

4

2

6

HD (4), T-cell (3), myeloid/leuk (8)

6.04 (3.43–10.64)

36.17 (25.44–51.43)

  1. ND not detailed, NA non-applicable, MALT mucosa-associated lymphoid tissue, DLBC Diffuse large B-cell lymphoma, MZ marginal zone lymphoma, MM myeloma multiple, Netherl Netherlands, Hosp hospital, Pop population, Classif classification, Hemat hematological, Myel Myeloma